Zynex Medical Electrotherapy Pain Management and Growth Strategy

Financial Highlights Zynex Financial Overview • 2021 full year guidance - Revenue $135 to $150 million, Adjusted EBITDA $15 to $25 million • 2021 second quarter guidance • Revenue $31.0M to $32.5M (Q2 2021 revenue ↑ 61% to 69% vs Q2 2020) • Adjusted EBITDA $3.0M to $4.0M Adding direct sales reps to reach 600 by the end of 2021 Selected Financials Quarter Ended March 31, 2021 vs 2020 • Net revenue ↑ 58% to $24.1M from $15.2M • Gross margin of 76% • Net loss $0.7M (Q1 seasonality and continued investment in growing sales force) • Adjusted EBITDA loss $0.4M • Orders 140% • Working capital $51.5M vs $52.1M at 12/31/20 • Cash $33.4M • No long-term debt ZYNEX MEDICAL" SQ

View entire presentation